Daily Intelligence Brief
Talc, Depo-Provera, and Hair Relaxer Drive 435 Weekly Federal Filings as J&J's Post-Bankruptcy Defense Posture Fuels Surge
The past seven days saw 435 new federal complaints across twenty-plus litigations, with Johnson & Johnson Talcum Powder Products Liability Litigation (MDL 2738) commanding 217 filings — nearly half the weekly volume — against a pending docket of roughly 67,376 claims, the largest active MDL in the federal system. The filing surge tracks J&J's confirmation that it will not appeal the March 2025 dismissal of its Red River Talc Chapter 11 — the third failed bankruptcy maneuver — forcing the company to defend claims on the merits after Judkins v. Johnson & Johnson was designated the first federal bellwether in July 2025. Intake momentum is building behind a $40 million California state-court bellwether verdict in December 2025 ($22M to Schulz and $18M to Kent) and cumulative historic verdicts exceeding $7 billion. Depo-Provera Products Liability Litigation (MDL 3140) added 45 filings and Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (MDL 3060) added 41, while the Uber Technologies, Inc., Passenger Sexual Assault Litigation (MDL 3084) added 22 amid sustained institutional-accountability intake.Baby Food Metals MDL Gains Traction With Nine New Filings as Florida Courts See Concentrated Activity
Baby Food Products Liability Litigation (MDL 3101) recorded 9 new federal complaints over the past week, all filed in Florida — 6 in the Middle District and 2 in the Southern District — marking the first significant multi-district filing cluster for the infant nutrition docket since its April 2024 centralization in the Northern District of California before Judge Jacqueline Scott Corley. The filings allege heavy metal contamination in commercial baby foods, with plaintiffs targeting Gerber, Beech-Nut, and Hain Celestial products. The Florida concentration — despite the MDL's California home — suggests coordinated plaintiff steering or favorable local counsel relationships, a pattern worth monitoring as the docket moves from direct-file activity toward structured pretrial proceedings. No bellwether selection timeline has been set, but the filing velocity indicates plaintiff firms are moving past initial case inventory assessment into active complaint drafting.Covidien Hernia Mesh MDL 3029 Adds Two Filings Before Rescheduled July Bellwether as Mediation Deadline Lapses
Covidien Hernia Mesh Products Liability Litigation (No. II) (MDL 3029) recorded 2 new federal complaints in the past week — 1:26-cv-11858 filed April 23 (Law Office of Kenneth J. Melrose APC) and 1:26-cv-11794 filed April 17 (Nigh Goldenberg Raso Vaughn PLLC) — both in the U.S. District Court for the District of Massachusetts before Judge Patti B. Saris. The intake arrives with the MDL's caseload at 2,387 pending federal actions as of April 1, 2026 against Medtronic subsidiary Covidien, and with the first bellwether trial schedule materially reshuffled: Judge Saris vacated the February 17, 2026 Patterson trial date to accommodate settlement mediation, which the court extended to a January 14, 2026 deadline. With that window now lapsed without a global deal, the court has set a second bellwether — involving a Mississippi plaintiff alleging complications from Covidien's Symbotex mesh (the same device line at issue in the vacated Patterson trial) — for trial beginning July 13, 2026. Discovery has produced nearly two million documents centering on whether Covidien's FDA 510(k) clearance pathway bypassed clinical validation, a record that will frame Daubert and summary-judgment briefing heading into the July trial window — distinct from the Bard Hernia Mesh Products Liability Litigation (MDL 2846) posture, where a global settlement has resolved the parallel docket.Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
